SCOPUS 정보 검색 플랫폼

Drug Information Journal

Volumn 34, Issue 3, 2000, Pages 753-760

The food and drug administration's fast track designation: Observations from the initial two years of this designation

(1) Cocchetto, D M a

a GLAXOSMITHKLINE (United States)

Author keywords

Fast track designation; FDA; FDAMA

Indexed keywords

ABACAVIR; ADEFOVIR; ADEFOVIR DIPIVOXIL; ADRENALIN; AMPRENAVIR; CISPLATIN; CITICOLINE; DAPTOMYCIN; EFAVIRENZ; ENFUVIRTIDE; ETANERCEPT; INTRADOSE; PRASTERONE; TEMOPORFIN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTICLE; CRITICAL ILLNESS; DRUG RESEARCH; EXPERIENCE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE POLICY; HEALTH PROGRAM; LAW; PRIORITY JOURNAL;

EID: 0033849461 PISSN: 00928615 EISSN: None Source Type: Journal
DOI: 10.1177/009286150003400311 Document Type: Article

Times cited : (2)

References (36)

1
- 0008266768
- Guidance for Industry Fast track drug development programs - designation, development and application review Rockville, MD; Food and Drug Administration
- (1998)

2
- 0008217115
- 21 CFR 312.81(a)

3
- 0000124662
- Investigational New Drug, Antibiotic, and Biological Drug Product Regulations; Procedures for Drugs Intended to Treat Life-Threatening and Severely Debilitating Illnesses. Interim rule
- (1988) Federal Register , vol.53 , pp. 41516-41524

4
- 0008220871
- Investigational New Drug, Antibiotic, and Biological Drug Product Regulations; Treatment Use and Sale
- (1987) Federal Register , vol.52 , pp. 19466-19477

5
- 0008266769
- FDA expects to grant 90% of 60 fast track requests received annually
- (1998) F-D-C Reports: The Pink Sheet , pp. 6

6
- 0008264949
- Fast track. Presentation at the Annual Conference of the Regulatory Affairs Professionals Society, October 3-6, 1999, Washington, DC
- Goldman, B.¹

7
- 0008227218
- Food and Drug Administration Center for Drug Evaluation and Research Manual of Policies and Procedures (MAPP) 60203 Priority Review Policy Rockville, MD: Food and Drug Administration; April 22, 1996. and Food and Drug Administration. Center for Biologics Evaluation and Review. Manual of Standard Operating Procedures and Policies (SOPP) 8405. Complete Review and Issuance of Action Letters. Rockville, MD: Food and Drug Administration
- (1998)

8
- 0008260002
- 21 CFR 314.50(d)(1)(iv)

9
- 0008188155
- Glaxo Wellcome Ziagen
- (1998) F-D-C Reports: The Pink Sheet , pp. 32

10
- 0008182850
- Gilead Sciences adefovir dipivoxil
- (1999) F-D-C Reports: The Pink Sheet , pp. 32

11
- 0008227890
- BioMarin will file 1999 BLA based on 10-patient clinical package
- (1999) F-D-C Reports: The Pink Sheet , pp. 25-26

12
- 0008222543
- BioMarin's MPS-1 filing delayed
- (1999) Scrip

13
- 0008250490
- Ilex/Lilly development agreement grows out of CRO contract for cancer drug
- (1999) F-D-C Reports: The Pink Sheet , pp. 31

14
- 0008182498
- Campath filed in the US
- (2000) Scrip

15
- 0008224316
- Vertex/Glaxo Wellcome Agenerase
- (1998) F-D-C Reports: The Pink Sheet , pp. 32

16
- 0008227891
- Matrix IntraDose
- (1999) F-D-C Reports: The Pink Sheet , pp. 28

17
- 0008228846
- US grants Matrix's IntraDose fast track status
- (1999) Scrip

18
- 0008222544
- Interneuron's CerAxon for stroke to be fast-tracked
- (1998) Scrip

19
- 0008216809
- Cubist
- (1999) F-D-C Reports: The Pink Sheet , pp. 28

20
- 0008183156
- Genentech's Herceptin 'fast-track' review aided by rolling BLA
- (1998) F-D-C Reports: The Pink Sheet , pp. 9

21
- 0008265823
- Immunex Enbrel
- (1998) F-D-C Reports: The Pink Sheet

22
- 0008216810
- Cell Pathways Aptosyn
- (1999) F-D-C Reports: The Pink Sheet , pp. 33

23
- 0008181553
- Positive results in SLE from Genelabs
- (1999) Scrip

24
- 0008264785
- Genelabs GL701 lupus NDA will be complete in second half of 2000
- (1999) F-D-C Reports: The Pink Sheet , pp. 23-24

25
- 0008182499
- Glaxo/Vertex's protease inhibitor gets fast-track status
- (1999) Scrip

26
- 0008220873
- Sugen's new sponsor is P and U; $650 mil deal supplants AstraZeneca
- (1999) F-D-C Reports: The Pink Sheer , pp. 21

27
- 0008263533
- Miravant's macular degeneration drug to be fast-tracked
- (1998) Scrip

28
- 0008182502
- Shaman hopes move from biotechnology to botanicals can rekindle magic
- (1999) F-D-C Reports: The Pink Sheet , pp. 18

29
- 0008180249
- Trimeris T-1249
- (1999) F-D-C Reports: The Pink Sheet , pp. 28

30
- 0008220874
- Foscan receives orphan status for head and neck cancer
- (1999) Scrip

31
- 0008219455
- Genentech Herceptin approval meets patient group deadline
- (1998) F-D-C Reports: The Pink Sheet , pp. 3

32
- 0008184992
- Purdue takes $100 million option on Altarex Mabs
- (1999) Scrip

33
- 0008259159
- Synsorb's product fast-tracked by FDA
- (2000) Scrip

34
- 0008280688
- Wyeth Lederle vaccines
- (1999) F-D-C Reports: The Pink Sheet , pp. 32

35
- 0008259160
- FDA public log of fast track designated indications needed - PhRMA
- (1999) F-D-C Reports: The Pink Sheet , pp. 7

36
- 0027117969
- New Drug, Antibiotic, and Biological Drug Product Regulations; Accelerated Approval. Final rule
- (1992) Federal Register , vol.57 , pp. 58942-58960

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.